Pessary treatment for pelvic organ prolapse and health-related quality of life: a review

Babet H. C. Lamers · Bart M. W. Broekman · Alfredo L. Milani

Received: 9 October 2010 / Accepted: 24 February 2011 / Published online: 7 April 2011 © The Author(s) 2011. This article is published with open access at Springerlink.com

Abstract Pessaries have been used to treat women with pelvic organ prolapse (POP) since the beginning of recorded history. This review aims to assess the effect of pessary treatment on the disease-specific, health-related quality of life in women with pelvic organ prolapse. After a Medline search using the Mesh term ‘pessary’ and critical appraisal, 41 articles were selected and used in this review. Pessaries are widely used to treat pelvic organ prolapse. It is minimally invasive and appears to be safe. Although there is evidence that the use of pessaries in the treatment of pelvic organ prolapse is effective in alleviating symptoms and that patient satisfaction is high, the follow-up in many published papers is short, and the use of validated urogynaecological questionnaires is limited. Comparison with surgical treatment of pelvic organ prolapse is rare and not assessed in a randomised controlled trial.

Keywords Pelvic organ prolapse · Pessaries · Pessary · Quality of life · Surgery · Urogenital

Introduction

Pessaries have been used to treat women with pelvic organ prolapse since the beginning of recorded history. Hippocrates described reduction of vaginal prolapse by placing a halved pomegranate soaked in wine into the vagina (Fig. 1) [1].

A variety of devices has been described over time [2]. Nowadays, most pessaries are made of silicone and are ring type pessaries with or without central support, Gellhorn pessaries and donut pessaries (Fig. 2) [3]. Pessaries are used in daily practice by more than 86% of gynaecologists and 98% of urogynaecologists [4, 5]. The ring with central support and the Gellhorn pessary are most frequently used and appear equally effective in relieving symptoms of genital prolapse and voiding dysfunction [6].

It is not clear which patients particularly benefit most from pessary treatment, what the side effects are and whether the therapeutic effect is high enough to condone possible side effects. Most important is whether pessary treatment reduces urogenital bother symptoms and which impact it has on health-related quality of life [7]. In the end, it is not the doctor’s but the patient’s opinion about the treatment that is most important. Health-related quality of life is one of the patient outcome measures (POM) and is measured and quantified in domain scores of validated urogynaecological questionnaires. The use of these validated questionnaires to assess health-related quality of life in surgery of pelvic organ prolapse (POP) is well established. Although pessary treatment is widely used for the treatment of pelvic organ prolapse as well, a (systematic) review on the quality of life following pessary treatment has not yet been published.

This review aims to assess the effects of pessary treatment on disease-specific health-related quality of life in women with POP.
Search strategy and selection criteria

We searched Medline (1966 to December 2010) using the Mesh term ‘pessary’ and limits ‘female’ AND ‘human’. This resulted in 726 articles. An additional search on Embase using the term ‘pessary’ and limits ‘human’ resulted in 633 articles. After screening of both title and abstract, we were left with 159 articles related to pelvic organ prolapse and pessary. This review focused solely on pessary treatment in pelvic organ prolapse. Therefore, articles regarding pessary treatment in urinary incontinence or other conditions were excluded. Guidelines on how to fit a pessary, case reports describing rare complications without any literature review and experts’ letters were excluded. From the remaining 41 articles which were considered useful, 13 articles were a review [2, 5, 8–18], and 28 articles were original research articles [3, 4, 6, 7, 19–43]. Only 10 articles [6, 19–21, 25, 27, 32, 34, 35, 41] met the exact criteria of the reviewers’ aim to assess the health-related quality of life in women with pelvic organ prolapse. Although the other articles did not meet these pre-specified criteria, they were considered useful in additional analyses, such as for example which women are most suitable for pessary treatment, successful fitting, dropout rates and management of pessary treatment. Table 1 shows a description of papers included in this review. This review was originally set up as a systematic review. After reviewing the articles, there was inconsistency in definitions such as successful fitting and dropout rates, sample sizes, and follow-up periods, and there was shortage of studies that met the exact criteria. Therefore, the goal of a systematic review could unfortunately not be achieved, but the available (or lack of) research articles did, to our opinion, justify the present review.

Patient suitability

Which patients are considered suitable for pessary treatment remains unclear from the literature. Patients themselves may have preconceived ideas, and both beliefs and attitudes regarding the aetiology and success of pessary treatment may influence their choice of treatment [3, 22, 31, 33].

Some factors contributing to patient’s choices appear to be independently associated with treatment choices of patients in a fairly predictable way. The probability of choosing pessary treatment over surgery increases as patients’ age rises and respectively decreases as stage of POP increases [31]. Women who already have undergone prior POP surgery are more eager to choose POP surgery again [31]. Women preferring surgery to pessary treatment for POP reported more bothersome symptoms related to POP and felt more affected by POP in their general well-being [33]. Furthermore, the majority of patients who were sexually active tended to prefer surgery above conservative treatment [33].

Failure of fitting and continuation of pessary use

Most papers reported that there are certain groups of patients that drop out. There are patients who initially do
not comfortably retain a pessary (mostly at their first visit). There is an additional group of patients who abandon pessary treatment after some weeks because of discomfort or repeated expulsions [30]. There is no agreement in the literature on what is considered successful pessary fitting. Some authors considered fitting successful if a pessary was perceived comfortable by a patient when retained during Valsalva and voiding, at the initial patient visit, while others considered fitting successful if a patient continued to use the pessary until the following doctor’s appointment [40]. Therefore, the rate of unsuccessful fitting and dropout ranges widely. Table 2 offers an overview of successful fitting and dropout rates of studies included in this review. In this review, we considered fitting to be successful if a patient comfortably retained a pessary at their first visit. A patient was considered to drop out if they abandoned pessary use at the following doctors’ appointment.

Most studies reported successful fitting rates to be over 85%. Risk factors that are reported to be responsible for unsuccessful pessary fitting are short vaginal length, a large genital hiatus, prior history of hysterectomy and prior surgical repairs of POP [37, 39].

The compartment and stage of POP have not been reported to have any influence on successful pessary fitting and should therefore not be a factor of patient selection for pessary treatment [39]. Continuation rates on the short-term range from 50% to 80% after 3 or 4 months. After 1 year of use, the continuation rates remain unchanged: 50–80%. Only two studies reported long-term continuation of pessary use over more than 1 year. One study reported a continued pessary use in 48% of patients for an average duration of 5.4 years [23]. A more recent study on the long term reported a 14% continued pessary use with a mean duration of 7 years [43].

An independent factor associated with the continued use of a pessary is age above 65 years. Sexually active women were more likely to continue wearing a pessary for a longer period of time [22, 26, 28].

### Improvement in POP-related bother and health-related quality of life

POP causes symptoms that have impact on patients’ daily activities and quality of life. Women with POP seem to have a negative body image compared to women without POP [44]. Women who seek medical advice perceive these symptoms bothersome enough to opt for treatment and strive to improve their perceived quality of life [44].

We found only few articles in which validated urogynaecological questionnaires were used to assess treatment effects on health-related quality of life [6, 19, 21, 27, 32, 34, 35, 41]. Two articles did not use validated questionnaires but measured improvement of POP symptoms and satisfaction in pessary users with questionnaires that
were not validated [20, 25]. Other questionnaires that were used were the Female Sexual Function Index Questionnaire (FSFI), the Pelvic Floor Distress Inventory (PFDI), the Pelvic Floor Impact Questionnaire (PFIQ), the Body Image Scale, the Sheffield Pelvic Organ Prolapse Symptom Questionnaire and the King’s Health Questionnaire. The PFDI and PFIQ have been validated for use in women with POP [41]. The body image scale evaluates a woman’s self-perception of her physical appearance, attractiveness, and satisfaction with her body. This questionnaire has been used in research on women with cancer and was considered valid and reliable for that group of patients, but is not yet validated for use in women with POP [45]. The FSFI is a validated questionnaire that refers to the domains of desire, arousal, lubrication, orgasm and satisfaction in sexual functioning [46]. The Sheffield prolapse questionnaire relates to the severity of POP specific symptoms, while the King’s Health Questionnaire evaluates domains of health-related quality of life [35]. These findings may have resulted of improvements in general well-being which may have altered patients’ self-esteem. These data are suggestive that a vaginal pessary does not negatively interfere with sexual activity and may even improve sexual functioning as a whole.

Patients’ satisfaction rates with medium-term pessary use are high (70–92%) [20, 25]. Pessary treatment for 3 months not only reduced POP-related bother symptoms but also caused improvement in quality of life and women’s perception of their body image [41].

A recently published study compared the effectiveness of pessaries with surgery in women with symptomatic POP [19]. The authors reported similar improvements in urinary, bowel, sexual function and quality of life parameters in both treatment arms. That suggests that pessary treatment in POP might be as effective as surgery in improving health-related quality of life.

| Author publication year [reference] | Number | Study design | Initially successful fitting, n (%)a | Dropout at follow-up, n (%)b | Follow-up in months |
|------------------------------------|--------|--------------|--------------------------------------|-----------------------------|---------------------|
| Clemons 2004 [24]                 | 100    | Prospective  | 94 (94)                              | 21 (22)                     | 0.5                 |
| Brincat 2004 [22]                 | 136    | Retrospective| Unknown                               | 54 (40)                     | 4                   |
| Clemons 2004 [26]                 | 59     | Prospective  | Unknown                               | 16 (27)                     | 12                  |
| Mutone 2004 [39]                  | 407    | Retrospective| 288 (71)                              | 120 (42)                    | 0.75                |
| Powers 2004 [42]                  | 32     | Retrospective| Unknown                               | 20 (63)                     | Unknown             |
| Broens-Oostveen 2004 [23]         | 192    | Retrospective| Unknown                               | 107 (52)                    | 64                  |
| Bai 2005 [20]                     | 104    | Retrospective| Unknown                               | 20 (19)                     | Unknown             |
| Hanson 2005 [30]                  | 1,216  | Retrospective| 1,043 (86)                            | 299 (29)                    | 3                   |
| Fernando 2006 [27]                | 203    | Prospective  | 203 (100)                             | 106 (52)                    | 4                   |
| Barber 2006 [21]                  | 42     | Prospective  | 42 (100)                              | 0 (0)                       | 3                   |
| Maito 2006 [37]                   | 120    | Retrospective| 103 (86)                              | 11 (11)                     | 6                   |
| Cundiff 2007 [6]                  | 134    | Randomised cross-over | 123 (92)                             | 49 (40)                     | 3                   |
| Komesu 2007 [34]                  | 64     | Prospective cohort study | Unknown                           | 28 (44)                     | 12                  |
| Jones 2008 [32]                   | 90     | Prospective cohort study | Unknown                           | 48 (53)                     | 3                   |
| Nager 2009 [40]                   | 255    | Randomised controlled trial | 235 (92)                             | No follow-up                | No follow-up        |
| Kuhn 2009 [35]                    | 73     | Prospective cohort study | Unknown                           | 40 (55)                     | 3                   |
| Sarma 2009 [43]                   | 273    | Retrospective | 167 (61)                              | 144 (86)                    | 84                  |
| Friedman 2010 [28]                | 150    | Retrospective | Unknown                           | 35 (23)                     | 12                  |
| Patel 2010 [41]                   | 75     | Prospective cohort study | 70 (93)                              | 21 (30)                     | 3                   |
| Abdool 2010 [19]                  | 359    | Prospective  | 359 (100)                             | 116 (32)                    | 12                  |

a Initially fitting
b Dropout at follow-up
| Author year | Number | Study design | Dropout, n (%) | Dropout reasons | Follow-up in months | Questionnaires used | Improved symptoms with pessary treatment | Worsened symptoms | Satisfaction rate |
|-------------|--------|--------------|----------------|-----------------|---------------------|---------------------|------------------------------------------|------------------|------------------|
| Clemons 2004 [25] | 100    | Prospective study | 27 (27) | Failure to retain pessary, Discomfort | 2 months | Questionnaire not further assessed | Bulge, Pressure, Discharge, Voiding, Urge incontinence, Stress incontinence | De novo stress urinary incontinence | 92% |
| Bai 2005 [20] | 104    | Retrospective study | 20 (19) | Failure to retain pessary, Discomfort, Inflammation | Unknown | Questionnaire not further assessed | | | |
| Fernando 2006 [27] | 203    | Prospective observational cohort study | 106 (52) | Failure to retain pessary, Pain/bleeding/discomfort, Worsening symptoms | 4 months | SPQ | | | |
| Barber 2006 [21] | 42     | Prospective crossover study | 0       | | 3 months | PFDI, PFIQ | Bulge, Urinary | | |
| Cundiff 2007 [6] | 134    | Randomised crossover study | 49 (37) | Failure to retain pessary, Quit study due to failure of pessary | 3 months ring, 3 months Gellhom | PFIQ, PFDI | Bulge, Urinary, Life impact urinary symptoms, Life impact pelvic organ prolapse | | |
| Komesu 2007 [34] | 64     | Prospective observational cohort study | 28 (44) | Failure to retain pessary, Discomfort | 12 months | PFDI | Bulge, Urinary, Stress incontinence | | |
| Jones 2008 [32] | 90     | Prospective observational cohort study | 48 (53) | Failure to retain pessary, Inadequate relief of symptoms | 3 months | PFDI | Bulge, Urinary | | |
| Kuhn 2009 [35] | 73     | Prospective observational cohort study | 40 (55) | Loss of pessary during daily activities or bowel emptying, Pain/discomfort, Desire for surgery, Worsening symptoms, Inability to remove insert/remove pessary | 3 months | SPQ, FSFI, KHQ | General health, Role limitations, Physical and social limitations, Incontinence impact, Personal relationships, Sexual desire, Lubrification, Sexual satisfaction, Bulge, Stool outlet problems | De novo stress urinary incontinence | |
| Patel 2010 [41] | 75     | Prospective observational cohort study | 21(28) | Failure to retain pessary, Desire for surgery, Discomfort | 3 months | PFDI, PFIQ, BIS | Body image, Quality of life, Bulge | | |
| Abdoool 2010 [19] | 359    | Prospective study | 116 (32) | Opted for surgery | 12 months | SPQ | Bulge, Pessary-related problems, Pressure, Urinary, Sexual function, Stool outlet problems | | |

Questionnaires used were Female Sexual Function Index (FSFI), Sheffield Prolapse Questionnaire (SPQ), King’s Health Questionnaire (KHQ), Pelvic Floor Distress Inventory (PFDI), Pelvic Floor Impact Questionnaire (PFIQ), and body image scale (BIS). Questionnaire not further assessed.
Improvement in POP-Q measurement

There may be a decrease in the size of the genital hiatus with continued pessary use. This decrease is detected even after 2 weeks of continuous pessary wearing [32]. There may also be an improvement in POP stage after 1 year of pessary treatment [29]. Such improvements may have been due to a transient effect of pessary use [29, 38]. Limitations of these papers are the small sample sizes. Whether this reduction in POP stage sustains at the long term and whether it is clinically relevant need further research.

Management and follow-up

Evidence is lacking on the type of pessary that is chosen, or who should be responsible for cleaning and changing pessaries and how often this should be performed [14, 30]. Ideally, the physician can teach a patient how to remove and replace the pessary herself. This increases patients’ autonomy, allowing her to use it and clean it when needed [5, 18]. In such a setting, follow-up could be on an annual basis [18]. Patients who are not willing or able to manage pessary care themselves require more frequent doctors (or nurse practitioner) visits. There is a lack of evidence on whether a pessary should be used in combination with hormone replacement therapy or pelvic floor exercises [3]. If HRT is prescribed, local HRT seems to be more beneficial in reducing side effects than systemic HRT or a combination of both [30]. HRT is particularly used to prevent vaginal irritation and ulceration due to pressure of the pessary in an older and atrophic vagina [17]. There is some evidence that local HRT plays a significant role in the initial success of fitting [30].

Complications and discomfort

The most common side effects of pessary use are a foul smell, vaginal discharge, bleeding, pain and constipation [43]. A recent study reported that 56% of women wearing a pessary reported one of these side effects [43]. Changing a pessary at frequent intervals could prevent this vaginal irritation. Therefore, it is helpful if the patient is willing and able to remove, clean and replace the pessary herself [18].

Rarely, pessaries cause major urinary, rectal and genital complications such as fistula, faecal impaction, hydrenephrosis and urosepsis [1]. These rare complications are almost exclusively related to a long period of use and negligence of care. With regular follow-up, the majority of pessary complications can be avoided and kept to a minimum [9].

Conclusion

Pessary treatment is widely used for the treatment of pelvic organ prolapse. It can be considered a patient-friendly, minimally invasive treatment and appears to be safe. Most studies reported successful fitting trial over 85%. Risk factors responsible for unsuccessful pessary fitting are short vaginal length, a large genital hiatus, prior history of hysterectomy and prior surgical repairs of POP. The compartment and stage of POP have not been reported to have any influence on successful pessary fitting. Fifty percent to 80% of women who were initially successfully fitted continued to use pessary at 1 year. Continuation rates at greater than 5 years range from 14% to 48%. Consistent in most reports though are the improvements in both bulge and irritative bladder symptoms and the high satisfaction rates.

Sexual activity appears not to be a contraindication for pessary treatment; on the contrary, it seems to have a positive effect on sexual functioning. In comparison with POP surgery, 1-year outcomes in terms of prolapse symptoms, sexual functioning and quality of life seem similar with pessary use.

Discussion

The aim of this review was to set up a systematic review on articles that address health-related quality of life in pessary treatment of pelvic organ prolapse. The limitation of this review is the limited availability of published studies on that issue. Another limitation is that in most published papers, follow-up periods were short, usually less than 12 months. Long-term outcomes on the other hand were inconsistent.

The use of validated urogynaecological questionnaires in pessary treatment is still limited. In POP surgery, the use of these validated tools is well established. The few papers in which urogynaecological questionnaires were used do suggest improvements in health-related quality of life following pessary treatment. Comparison with other prolapse therapies is rare and, if so, not yet assessed in a randomised controlled trial.

More research is indicated, and it is our opinion that a randomised controlled trial comparing pessary use with surgical treatments of POP should be undertaken to determine its therapeutic position in the management of pelvic organ prolapse. Outcome measures of such a trial
should be the change in urogenital bother and quality of life scores.

- Gelhorn and ring with support prescribed most frequently
- Sexual activity or degree of prolapse should not be a contraindication of pessary treatment
- Failure to fit 15%
- If HRT is prescribed, local HRT is sufficient
- Common side effects are bleeding, vaginal discharge, pain, constipation and odour.
- Side effects appear in 56% of women with long term pessary use.

Effect of pessary treatment
- Improvement in bulge symptoms
- Improvement in irritative bladder symptoms
- Increase in frequency and satisfaction of sexual behaviour
- Improvement in perception of body image
- Reported satisfaction rate 70-92%
- Comparison with surgery similar outcomes after 1 year follow up.

Conflicts of interest None.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References
1. Jelovsek JE, Maher C, Barber MD (2007) Pelvic organ prolapse. Lancet 369(9566):1027–1038, 24
2. Adams E, Thomson A, Maher C, Hagen S. (2004) Mechanical devices for pelvic organ prolapse in women. Cochrane Database Syst Rev (2):CD004010
3. Cundiff GW, Weidner AC, Visco AG, Bump RC, Addison WA (2000) A survey of pessary use by members of the American Urogynecologic Society. Obstet Gynecol 95(6 Pt 1):931–935
4. Richter HE, Burgio KL, Brubaker L, Nygaard IE, Ye W, Weidner A et al (2010) Contienence pessary compared with behavioral therapy or combined therapy for stress incontinence: a randomized controlled trial. Obstet Gynecol 115(3):609–617, 2010 March
5. Atump SD (2009) Pessary use and management for pelvic organ prolapse. Obstet Gynecol Clin North Am 36(3):541–563
6. Cundiff GW, Amundsen CL, Bent AE, Coates KW, Schaffer JL, Strobbehn K et al (2007) The PESSRI study: symptom relief outcomes of a randomized crossover trial of the ring and Gelhorn pessaries. Am J Obstet Gynecol 196(4):405–408
7. Komse YM, Rogers RG, Rode MA, Craig EC, Schrader RM, Gallegos KA et al (2008) Patient-selected goal attainment for pessary wearers: what is the clinical relevance? Am J Obstet Gynecol 198(5):577–577
8. Anders K (2004) Devices for continence and prolapse. BJOG 111 (Suppl 1):61–66
9. Arias BE, Ridgeway B, Barber MD (2008) Complications of neglected vaginal pessaries: case presentation and literature review. Int Urogynecol J Pelvic Floor Dysfunct 19(8):1173–1178
10. Doshani A, Teo RE, Mayne CJ, Tincello DG (2007) Uterine prolapse. BMJ 335(7624):819–823, 20
11. Onwude JL. (2007) Genital prolapse in women. Clin Evid (Online)
12. Shagam JY (2006) Pelvic organ prolapse. Radiol Technol 77 (5):389–400
13. Shah SM, Sultan AH, Thakar R (2006) The history and evolution of pessaries for pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct 17(2):170–175
14. Thakar R, Stanton S (2002) Management of genital prolapse. BMJ 324(7348):1258–1262, 25
15. Trowbridge ER, Fenner DE (2005) Conservative management of pelvic organ prolapse. Clin Obstet Gynecol 48(3):668–681
16. Trowbridge ER, Fenner DE (2007) Practicalities and pitfalls of pessaries in older women. Clin Obstet Gynecol 50(3):709–719
17. Vierhout ME (2004) The use of pessaries in vaginal prolapse. Eur J Obstet Gynecol Reprod Biol 117(1):4–9, 10
18. Weber AM, Richter HE (2005) Pelvic organ prolapse. Obstet Gynecol 106(3):615–634
19. Abdoon Z, Thakar R, Sultan AH, Oliver RS (2010) Prospective evaluation of outcome of vaginal pessaries versus surgery in women with symptomatic pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct 16
20. Bai SW, Yoon BS, Kwon JY, Shin JS, Kim SK, Park KH (2005) Survey of the characteristics and satisfaction degree of the patients using a pessary. Int Urogynecol J Pelvic Floor Dysfunct 16 (3):182–186
21. Barber MD, Walters MD, Cundiff GW (2006) Responsiveness of the Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ) in women undergoing vaginal surgery and pessary treatment for pelvic organ prolapse. Am J Obstet Gynecol 194(5):1492–1498
22. Brincat C, Kenton K, Pat FM, Brubaker L (2004) Sexual activity predicts continued pessary use. Am J Obstet Gynecol 191(1):198–200
23. Broens-Oostveen MC, Mom RM, Lagro-Janssen AL (2004) Genital prolapse; treatment and course in four general practices. Ned Tijdschr Geneeskd 148(29):1444–1448, 17
24. Clemons JL, Aguilar VC, Tillinghast TA, Jackson ND, Myers DL (2004) Risk factors associated with an unsuccessful pessary fitting trial in women with pelvic organ prolapse. Am J Obstet Gynecol 190(2):345–350
25. 122Clemons JL, Aguilar VC, Tillinghast TA, Jackson ND, Myers DL (2004) Patient satisfaction and changes in prolapse and urinary symptoms in women who were fitted successfully with a pessary for pelvic organ prolapse. Am J Obstet Gynecol 190(4):1025–1029
26. Clemons JL, Aguilar VC, Sokol ER, Jackson ND, Myers DL (2004) Patient characteristics that are associated with continued pessary use versus surgery after 1 year. Am J Obstet Gynecol 191(1):159–164
27. Fernando RJ, Thakar R, Sultan AH, Shah SM, Jones PW (2006) Effect of vaginal pessaries on symptoms associated with pelvic organ prolapse. Obstet Gynecol 108(1):93–99
28. Friedman S, Sandhu KS, Wang C, Mikhail MS, Banks E (2010) Factors influencing long-term pessary use. Int Urogynecol J Pelvic Floor Dysfunct 21(6):673–678
29. Handa VL, Jones M (2002) Do pessaries prevent the progression of pelvic organ prolapse? Int Urogynecol J Pelvic Floor Dysfunct 13(6):349–351
30. Hanson LA, Schulz JA, Flood CG, Cooley B, Tam F (2006) Vaginal pessaries in managing women with pelvic organ prolapse and urinary incontinence: patient characteristics and factors contributing to success. Int Urogynecol J Pelvic Floor Dysfunct 17(2):155–159
31. Heit M, Rosenquist C, Culligan P, Graham C, Murphy M, Shott S (2003) Predicting treatment choice for patients with pelvic organ prolapse. Obstet Gynecol 101(6):1279–1284
32. Jones K, Yang L, Lowder JL, Meyn L, Ellison R, Zyczynski HM et al (2008) Effect of pessary use on genital hiatus measurements in women with pelvic organ prolapse. Obstet Gynecol 112(3):630–636
33. Kapoor DS, Thakar R, Sultan AH, Oliver R (2009) Conservative versus surgical management of prolapse: what dictates patient choice? Int Urogynecol J Pelvic Floor Dysfunct 20(10):1157–1161
34. Komesu YM, Rogers RG, Rode MA, Craig EC, Gallegos KA, Montoya AR et al (2007) Pelvic floor symptom changes in pessary users. Am J Obstet Gynecol 197(6):620–626
35. Kuhn A, Bapst D, Stadlmayr W, Vits K, Mueller MD (2009) Sexual and organ function in patients with symptomatic prolapse: are pessaries helpful? Fertil Steril 91(5):1914–1918
36. Lowenstein L, Gamble T, Sanses TV, van RH, Carberry C, Jakus S, Pham T et al (2010) Changes in sexual function after treatment for prolapse are related to the improvement in body image perception. J Sex Med 7(2 Pt 2):1023–1028
37. Maito JM, Quam ZA, Craig E, Danner KA, Rogers RG (2006) Predictors of successful pessary fitting and continued use in a nurse-midwifery pessary clinic. J Midwifery Womens Health 51(2):78–84
38. Matsubara S, Ohki Y (2010) Can a ring pessary have a lasting effect to reverse uterine prolapse even after its removal? J Obstet Gynaecol Res 36(2):459–461
39. Mutone MF, Terry C, Hale DS, Benson JT (2005) Factors which influence the short-term success of pessary management of pelvic organ prolapse. Am J Obstet Gynecol 193(1):89–94
40. Nager CW, Richter HE, Nygaard I, Paraiso MF, Wu JM, Kenton K et al (2009) Incontinence pessaries: size, POPQ measures, and successful fitting. Int Urogynecol J Pelvic Floor Dysfunct 20(9):1023–1028
41. Patel M, Mellen C, O’Sullivan DM, Lasala CA. (2010) Impact of pessary use on prolapse symptoms, quality of life, and body image. Am J Obstet Gynecol 18
42. Powers K, Lazarou G, Wang A, LaCombe J, Bensinger G, Greston WM et al (2006) Pessary use in advanced pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct 17(2):160–164
43. Sarma S, Ying T, Moore KH (2009) Long-term vaginal ring pessary use: discontinuation rates and adverse events. BJOG 116(13):1715–1721
44. Jelovsek JE, Barber MD (2006) Women seeking treatment for advanced pelvic organ prolapse have decreased body image and quality of life. Am J Obstet Gynecol 194(5):1455–1461
45. Hopwood P, Fletcher I, Lee A, Al GS (2001) A body image scale for use with cancer patients. Eur J Cancer 37(2):189–197
46. Novi JM, Jeronis S, Morgan MA, Aya LA (2005) Sexual function in women with pelvic organ prolapse compared to women without pelvic organ prolapse. J Urol 173(5):1669–1672